PEG-modified Upconversion Nanoparticle Production Service
Overview
PEG-modified upconversion nanoparticles (UCNPs) combine the unique optical properties of upconversion materials with the beneficial properties of polyethylene glycol (PEG) modification. The upconversion properties enable the nanoparticles to convert low-energy infrared light into high-energy visible light, opening up several applications in areas such as bioimaging, biosensing, and photodynamic therapy. The PEG modification enhances the nanoparticle's biocompatibility and stability in biological systems. The PEG helps to minimize non-specific interactions and immune responses and prolongs nanoparticle circulation time in vivo. This modification also improves the solubility and dispersion of nanoparticles, facilitating their delivery and targeting to specific sites. In research and potential clinical applications, PEG-modified UCNPs provide a powerful tool for researchers to explore and develop novel therapeutic strategies and imaging techniques.
Unleash the Potential with Our Exceptional PEG-Modified UCNP Production
CD BioGlyco has made significant advancements in the GlycoNano™ Platform, enabling us to offer a comprehensive range of professional services. These services include not only Glyconanoparticle Development Service, Glycol Nanohydrogel Development Service, and Glycol Nanorod Production Service, but also several other specialized offerings. Among them, our PEG Glyconanoparticle Production Service has gained wide acclaim and popularity among our customers. This service is renowned for its high quality, efficiency, and precision, which have met and exceeded the expectations of our clients. The details of our PEG-modified UCNPs production service are as follows.
Synthetic Process
Firstly, we synthesize UCNPs with an inorganic core@shell structure where the core is Yb3+ and Tm3+ doped NaYF4 and the shell is NaYF4. Subsequently, the surface modification is carried out and the synthesized UCNPs are intercalated using the amphiphilic polymer. The amphiphilic polymer (e.g. PMAO) can be coated on the surface of UCNPs through the solvent evaporation technique. Next, cross-linking is performed using poly(ethylene glycol) diglycol ether (PEG-DGE). PEG-DGE with a molecular weight of 500 is selected to form a "core-crown" structure. The aqueous dispersion containing UCNPs is centrifuged and resuspended in PBS buffer, and a certain amount of aqueous PEG-DGE is added. The mixture undergoes vortexing, sonication, heating, and stirring. Finally, the mixture is centrifuged once again to remove unreacted cross-linkers and the precipitate is resuspended in PBS buffer.
Characterization & Biocompatibility Testing
In characterizing PEG-modified UCNPs, we use transmission electron microscopy (TEM) to image UCNPs. Samples are observed by dilution, sonication, and dropwise addition to a copper grid coated with 0.3% pioloform. This method provides information on the morphology and size of the nanoparticles. We analyze the pure UCNPs and their modified samples with PMAO and PEG-DGE by using Fourier transform infrared spectroscopy (FTIR), which can help to confirm the presence of PEG-modified chemical structures and functional groups.
Our experts determine the concentration of non-adsorbed serum proteins in the presence of UCNPs by the Bradford method to assess the interaction of UCNPs with biological fluids. We analyze blood samples using a customized anti-Stokes fluorescence microscope to observe the distribution and amount of UCNPs in the blood.
Workflow
The workflow of our PEG-modified UCNP production is shown below.

Applications
- Due to its unique upconversion luminescence properties, it can perform high-resolution and high-contrast imaging in deep tissues, helping researchers to see cells, tissues, and organs in organisms more clearly.
- It can be used to detect various molecules and ions in living organisms, such as proteins, nucleic acids, and metal ions, providing a sensitive and accurate method for disease monitoring.
- It can be used to label and track specific types of cells to study cell migration, differentiation, and function.
Advantages
- Our efficient production process ensures the preparation of large quantities of nanoparticles with consistent properties for large-scale applications.
- We use mild preparation conditions to minimize damage to the structure and properties of the nanoparticles and to ensure their quality and activity.
- Our advanced production technology allows for precise control of the size and shape of the nanoparticles as a means of optimizing their optical properties and biodistribution.
Publication Data
Technologies: TEM, X-ray diffraction (XRD), Scanning electron microscopy (SEM), Atomic force microscopy (AFM)
Journal: Chemical Society Reviews
Published: 2015
IF: 40.4
Results: The main research of this article is about the surface modification of photonic UCNPs and their characterization for bioanalytical applications. The ability of UCNPs to be excited by near-infrared light and to emit visible light enables them to exhibit low autofluorescence and light scattering in biological samples, thus showing a wide range of potential applications in background interference-free imaging. Surface modification methods for photonic UCNPs mentioned in the article include ligand exchange, ligand modification, ligand interaction, and layer deposition. In addition, the article discusses different analytical methods for assessing the progress and success of surface functionalization, including nuclear magnetic resonance (NMR) techniques, UV absorption spectroscopy, chromatographic reagents, and fluorescent labeling.
Fig.1 The impact of a core-shell design on the upconversion luminescence of NaYF4:Yb,Er nanocrystals under 980 nm excitation. (Sedlmeier & Gorris, 2015)
Frequently Asked Questions
- How to ensure the quality and performance of nanoparticles during production?
First of all, the quality and purity of raw materials should be strictly controlled, and high-quality and high-purity starting materials should be selected to minimize the influence of impurities. It is important to precisely control the reaction conditions, such as temperature, reaction time, solution concentration, pH value, etc., because these factors are crucial to the formation and properties of nanoparticles. At the same time, we monitor the reaction process in real time and use analytical techniques, such as spectroscopy and particle size analysis, to understand the situation and make adjustments. - Is it possible to customize PEG-modified UCNPs for specific properties?
Based on the detailed and specific requirements of our clients, we make rational, precise, and effective adjustments to the production process and all relevant parameters in a comprehensive and multi-dimensional manner.
CD BioGlyco is dedicated to offering you the outstanding PEG-modified UCNPs production service. Our devoted team, equipped with vast knowledge and sophisticated techniques, has a strong passion for creating high-quality PEG-modified UCNPs. If you are interested in our service, please contact us without any restraint!
Reference
- Sedlmeier, A.; Gorris, H.H. Surface modification and characterization of photon-upconverting nanoparticles for bioanalytical applications. Chemical Society Reviews. 2015, 44(6): 1526-1560.
Quick Links
Resources
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform




